COSCIENS Biopharma Inc. (LON:0UGB)

COSCIENS Biopharma Statistics

Total Valuation

LON:0UGB has a market cap or net worth of GBP 6.11 million. The enterprise value is 969,586.

Market Cap	6.11M
Enterprise Value	969,586

Important Dates

The next estimated earnings date is Friday, November 7, 2025.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	1.79M
Shares Outstanding	n/a
Shares Change (YoY)	+62.42%
Shares Change (QoQ)	+0.96%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.89
PB Ratio	1.18
P/TBV Ratio	1.18
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.07
EV / Sales	0.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.07

Financial Position

The company has a current ratio of 2.96, with a Debt / Equity ratio of 0.32.

Current Ratio	2.96
Quick Ratio	2.17
Debt / Equity	0.32
Debt / EBITDA	n/a
Debt / FCF	-0.12
Interest Coverage	-75.42

Financial Efficiency

Return on equity (ROE) is -113.08% and return on invested capital (ROIC) is -34.66%.

Return on Equity (ROE)	-113.08%
Return on Assets (ROA)	-16.64%
Return on Invested Capital (ROIC)	-34.66%
Return on Capital Employed (ROCE)	-47.01%
Revenue Per Employee	172,293
Profits Per Employee	-343,819
Employee Count	40
Asset Turnover	0.24
Inventory Turnover	2.06

Taxes

In the past 12 months, LON:0UGB has paid 708,733 in taxes.

Income Tax	708,733
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -97.91% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-97.91%
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	42.16
Average Volume (20 Days)	209

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, LON:0UGB had revenue of GBP 6.89 million and -13.75 million in losses. Loss per share was -4.36.

Revenue	6.89M
Gross Profit	3.23M
Operating Income	-7.54M
Pretax Income	-13.04M
Net Income	-13.75M
EBITDA	-6.71M
EBIT	-7.54M
Loss Per Share	-4.36

Balance Sheet

The company has 6.81 million in cash and 1.65 million in debt, giving a net cash position of 5.16 million.

Cash & Cash Equivalents	6.81M
Total Debt	1.65M
Net Cash	5.16M
Net Cash Per Share	n/a
Equity (Book Value)	5.18M
Book Value Per Share	1.63
Working Capital	7.97M

Cash Flow

In the last 12 months, operating cash flow was -12.48 million and capital expenditures -805,810, giving a free cash flow of -13.29 million.

Operating Cash Flow	-12.48M
Capital Expenditures	-805,810
Free Cash Flow	-13.29M
FCF Per Share	n/a

Margins

Gross margin is 46.84%, with operating and profit margins of -109.44% and -199.56%.

Gross Margin	46.84%
Operating Margin	-109.44%
Pretax Margin	-189.27%
Profit Margin	-199.56%
EBITDA Margin	-97.36%
EBIT Margin	-109.44%
FCF Margin	n/a

Dividends & Yields

LON:0UGB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-62.42%
Shareholder Yield	n/a
Earnings Yield	-225.11%
FCF Yield	-217.55%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 21, 2022. It was a reverse split with a ratio of 0.04.

Last Split Date	Jul 21, 2022
Split Type	Reverse
Split Ratio	0.04

Scores

LON:0UGB has an Altman Z-Score of -0.98 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.98
Piotroski F-Score	3